Capricor Therapeutics, Inc. (CAPR)’s Stock Is Sell After Touching Yearly Low

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Logo

Investors sentiment decreased to 0.67 in 2018 Q4. Its down 1.33, from 2 in 2018Q3. It worsened, as 1 investors sold Capricor Therapeutics, Inc. shares while 5 reduced holdings. 1 funds opened positions while 3 raised stakes. 1.51 million shares or 26.24% less from 2.05 million shares in 2018Q3 were reported.
Citadel Advisors Llc owns 33,047 shares or 0% of their US portfolio. Bank & Trust Of Mellon Corporation has invested 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Royal Retail Bank Of Canada accumulated 34 shares. Vanguard Grp Inc Inc, a Pennsylvania-based fund reported 305,759 shares. Bank Of America Corporation De, a North Carolina-based fund reported 5,500 shares. 118,686 were reported by Geode Cap Management Limited Liability Com. Fin Architects Inc accumulated 0% or 2,000 shares. Moreover, Apriem Advisors has 0.01% invested in Capricor Therapeutics, Inc. (NASDAQ:CAPR) for 50,000 shares. Moreover, Brown Advisory has 0% invested in Capricor Therapeutics, Inc. (NASDAQ:CAPR) for 852,566 shares. Northern Trust reported 0% of its portfolio in Capricor Therapeutics, Inc. (NASDAQ:CAPR). New York-based Blackrock has invested 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Virtu Financial Llc reported 20,254 shares. The Pennsylvania-based Cordasco Networks has invested 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR).

The stock of Capricor Therapeutics, Inc. (NASDAQ:CAPR) hit a new 52-week low and has $0.30 target or 5.00 % below today’s $0.32 share price. The 7 months bearish chart indicates high risk for the $10.98M company. The 1-year low was reported on May, 17 by If the $0.30 price target is reached, the company will be worth $548,950 less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 14.03% or $0.0519 during the last trading session, reaching $0.3181. About 957,870 shares traded or 377.07% up from the average. Capricor Therapeutics, Inc. (NASDAQ:CAPR) has declined 71.97% since May 17, 2018 and is downtrending. It has underperformed by 76.34% the S&P500.

More notable recent Capricor Therapeutics, Inc. (NASDAQ:CAPR) news were published by: which released: “Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q2 2018 Results – Earnings Call Transcript – Seeking Alpha” on August 09, 2018, also with their article: “PTC’s Translarna OK’d in Brazil for DMD – Seeking Alpha” published on April 29, 2019, published: “The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs – Yahoo Finance” on May 11, 2019. More interesting news about Capricor Therapeutics, Inc. (NASDAQ:CAPR) were released by: and their article: “Capricor Therapeutics Presents Results of Studies of CAP-2003 at Gordon Research Conference on Extracellular Vesicles – GlobeNewswire” published on August 21, 2018 as well as‘s news article titled: “Capricor Therapeutics, Inc. to Host Earnings Call – Yahoo Finance” with publication date: May 13, 2019.

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The company has market cap of $10.98 million. The company's development stage drug candidates for cardiovascular diseases include CAP-1002 that is in Phase II clinical trials; and CAP-2003, which is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions. It currently has negative earnings.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.